Chris Schade

Chris joined Flagship Pioneering as a Growth Partner in 2023. In this role, he helps scale and grow Flagship-founded bioplatform companies, working together with leaders at Flagship and its ecosystem of companies on organizational development, long-term strategy, financing, and business development.

Chris joined Flagship with more than twenty years of public and private pharmaceutical and biotechnology industry experience. Most recently he was President and Chief Executive Officer of Aprea Therapeutics where he served as a member of the board since 2016, including as Chairman since 2020. Chris has also served in executive leadership positions at several emerging biotech companies including: Chief Executive Officer of Novira, a privately held antiviral drug discovery company until it was acquired by Johnson & Johnson; Chief Financial Officer of Omthera Pharmaceuticals, Inc., a Nasdaq-listed specialty pharmaceuticals company focused on new therapies for dyslipidemia until it was acquired by AstraZeneca Plc; and, Senior Vice President of Administration and Chief Financial Officer at Medarex, Inc, a biopharmaceutical company focused on antibody-based therapeutic products for oncology, inflammation, autoimmune disorders, and infectious diseases until it was acquired by Bristol-Myers Squibb. Before joining Medarex, Chris served as Managing Director at Merrill Lynch in London and for nearly twenty years held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co.

Chris currently serves on the board of directors of Integra LifeSciences Inc., where he chairs the Audit and Finance Committees. He received an M.B.A. from the Wharton School at the University of Pennsylvania and an A.B. from Princeton University.